ENTREPRENEURSHIP ARTICLES

• If AI Can't Read Your Science, Investors Won't Either

  As investors deploy AI to screen thousands of deals at once, life sciences founders who keep their story locked behind NDAs risk never making it past the first automated filter.

• Execution Debt In Early Drug Discovery: The Hidden Risk That Undermines Promising Biology

  Understanding how execution debt forms, how it compounds, and how to prevent it is central to building durable discovery programs.

• Thoughtful Supply Strategy Is No Longer Optional In Drug Development

  In drug discovery and development, supply chain decisions are often treated as a downstream concern. In reality, supply strategy is a development decision from the very beginning.

• Annual Reflections And Predictions From The Editors' Roundtable

  Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.

• The Unlikely Weapon Against Fentanyl: Your Immune System

  ARMR Sciences Inc. has developed a vaccine designed with a novel adjuvant, dmLT, to neutralize fentanyl in the bloodstream before it reaches the central nervous system and binds to μ-opioid receptors (MORs). 

• 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026

  Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.

• GO‑4 Drug Combo Offers New Hope for Treating Late-Stage BRCA/PALB2-Mutated Cancers

  General Oncology’s GO‑4 is an investigational product combining melphalan, BCNU, hydroxocobalamin, and ascorbic acid. The company's CEO, Jeff Glazier shared how the combo is designed to shut down DNA repair and resensitize hard‑to‑treat tumors to chemotherapy for patients with advanced pancreatic or breast cancer.

• OpenFold3 Released: Redefining The Limits Of Protein Prediction Models

  OpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.

• Five Takeaways from BIO 2025 and Why You Should Stay Tuned

  New chief editor of Drug Discovery Online shares insights from BIO 2025’s global biotech gathering and spotlights the impacts to early-stage drug research.

• FDA Seeks Comment On ICH Q9(R1) Quality Risk Management

  ICH has revised Q9 Quality Risk Management, providing principles and tools that can be applied throughout the product life cycle of drug substances, drug products, biological, and biotech products. The FDA, a founding member of the ICH, plays a major role in the development of ICH guidelines, which FDA then adopts and issues as guidance to industry.